Anzeige
Mehr »
Samstag, 13.06.2026 - Börsentäglich über 12.000 News
Diese Aktie anschauen - Kurz vor Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40F8M | ISIN: US3847471014 | Ticker-Symbol: NL0
Tradegate
12.06.26 | 19:34
50,96 Euro
-1,39 % -0,72
1-Jahres-Chart
GRAIL INC Chart 1 Jahr
5-Tage-Chart
GRAIL INC 5-Tage-Chart
RealtimeGeldBriefZeit
51,1451,3612.06.
51,1252,2212.06.

Aktuelle News zur GRAIL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoWhy Grail Could Be the Sleeper Stock Everyone's About to Notice12
05.06.Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now)2
GRAIL Aktie jetzt für 0€ handeln
05.06.Unsicherheit bei FDA-Zulassung: Goldman Sachs stuft Grail-Aktie mit "Neutral" ein16
05.06.Grail stock initiated at Neutral by Goldman Sachs on FDA uncertainty24
04.06.Is Grail Stock a Bad-News Buy After Its Recent Pullback?1
04.06.Why Grail Stock Popped Today3
01.06.GRAIL, Inc. - 8-K, Current Report2
01.06.Why Grail Shares Crashed Today7
31.05.GRAIL, Inc.: GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting614The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the...
► Artikel lesen
30.05.GRAIL, Inc.: GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting160No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri® Blood Test Reduced...
► Artikel lesen
25.05.Grail's Slump Enters Week 10. Is There Any End in Sight?16
06.05.GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations20
05.05.GRAIL, Inc.: GRAIL Reports First Quarter 2026 Financial Results424Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into...
► Artikel lesen
05.05.GRAIL, Inc. - 8-K, Current Report1
21.04.GRAIL präsentiert neue Studiendaten zum Krebstest Galleri auf ASCO-Tagung11
10.04.Hedge Fund and Insider Trading News: Chris Rokos, Crispin Odey, Bill Ackman, David Tepper, Saba Capital Management, Tudor Investment Corp, Impactive Capital, Grail Inc (GRAL), Amkor Technology Inc (AMKR), and More11
10.04.GRAIL rated new Neural at Mizuho and Piper after study setback2
10.04.Mizuho initiates Grail stock coverage with neutral rating on MCED outlook4
10.04.Mizuho startet Coverage für Grail mit "Neutral"-Rating und verweist auf unsichere Aussichten3
10.04.Piper Sandler initiates Grail stock coverage with neutral rating4
Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1